{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:43:16Z","timestamp":1790793796402,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004621","name":"Kerman University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.biopha.2018.07.140","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T13:11:13Z","timestamp":1532956273000},"page":"1742-1750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells"],"prefix":"10.1016","volume":"106","author":[{"given":"Narges","family":"Ghasemimehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Farsinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8626-4853","authenticated-orcid":false,"given":"Rooholla","family":"Mirzaee Khalilabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinat","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9869-0147","authenticated-orcid":false,"given":"Ahmad","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.07.140_bib0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.blre.2015.01.001","article-title":"Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy","volume":"29","author":"Mei","year":"2015","journal-title":"Blood Rev."},{"issue":"15","key":"10.1016\/j.biopha.2018.07.140_bib0010","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"March","key":"10.1016\/j.biopha.2018.07.140_bib0015","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"issue":"14","key":"10.1016\/j.biopha.2018.07.140_bib0020","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9881","key":"10.1016\/j.biopha.2018.07.140_bib0025","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet (Elsevier Ltd.)"},{"key":"10.1016\/j.biopha.2018.07.140_bib0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2217\/pgs.14.106","article-title":"Pharmacogenetics of childhood acute lymphoblastic leukemia","volume":"15","author":"Lopez-lopez","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.biopha.2018.07.140_bib0035","first-page":"599","article-title":"Discrimination of the effects of doxorubicin on two different breast cancer cell lines on account of multidrug resistance and apoptosise","volume":"79","author":"Oncul","year":"2017","journal-title":"Pharm. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2018.07.140_bib0040","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3892\/ijo.2016.3558","article-title":"Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines","volume":"49","author":"Pilco-Ferreto","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2018.07.140_bib0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/cvr\/cvs201","article-title":"mTOR : good, bad, or ugly?","author":"Zhang","year":"2012","journal-title":"Cardiovasc. Res."},{"issue":"July (7)","key":"10.1016\/j.biopha.2018.07.140_bib0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorna","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.biopha.2018.07.140_bib0055","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00005-009-0051-8","article-title":"Cardiomyocyte death in doxorubicin-induced cardiotoxicity","author":"Zhang","year":"2009","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"issue":"2","key":"10.1016\/j.biopha.2018.07.140_bib0060","doi-asserted-by":"crossref","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.140_bib0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0305-7372(03)00140-3","article-title":"Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?","volume":"30","author":"Plasschaert","year":"2004","journal-title":"Cancer Treat. Rev."},{"issue":"March","key":"10.1016\/j.biopha.2018.07.140_bib0070","article-title":"A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell line","author":"Shi","year":"2015","journal-title":"Target. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2018.07.140_bib0075","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ctrv.2012.06.007","article-title":"Novel anticancer therapeutics targeting telomerase","volume":"39","author":"Ruden","year":"2013","journal-title":"Cancer Treat. Rev. (Elsevier Ltd.)"},{"issue":"March","key":"10.1016\/j.biopha.2018.07.140_bib0080","first-page":"69","article-title":"Telomerase activity and telomere length in malignant cells of children with acute lymphoblastic leukemia","volume":"25","author":"Kustanovich","year":"2003","journal-title":"Exp. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2018.07.140_bib0085","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/0008-5472.CAN-13-3568","article-title":"Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies","volume":"74","author":"Li","year":"2014","journal-title":"Cancer Res."},{"issue":"July","key":"10.1016\/j.biopha.2018.07.140_bib0090","first-page":"657","article-title":"Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991","volume":"1","author":"Seimiya","year":"2002","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.biopha.2018.07.140_bib0095","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1007\/s13277-015-3575-z","article-title":"MST-312 induces G2\/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-\u03baB pathway","volume":"36","author":"Fatemi","year":"2015","journal-title":"Tumor Biol."},{"issue":"1","key":"10.1016\/j.biopha.2018.07.140_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-13-232","article-title":"Targeting DNA-PKcs and telomerase in brain tumour cells","volume":"13","author":"Gurung","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2018.07.140_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-10-96","article-title":"Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer","volume":"10","author":"Serrano","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2018.07.140_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-133","article-title":"siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells","volume":"9","author":"Dong","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2018.07.140_bib0115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3892\/ijo.2016.3546","article-title":"Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase","author":"Chung","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2018.07.140_bib0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/10245332.2016.1275426","article-title":"Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells","volume":"22","author":"Bashash","year":"2017","journal-title":"Hematology (Taylor & Francis)"},{"key":"10.1016\/j.biopha.2018.07.140_bib0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejmech.2016.09.028","article-title":"Targeting telomerase with radiolabeled inhibitors","volume":"125","author":"Waghorn","year":"2017","journal-title":"Eur. J. Med. Chem. (Elsevier Masson SAS)"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218339696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218339696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:36:11Z","timestamp":1750865771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218339696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":25,"alternative-id":["S0753332218339696"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.140","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}